Sage Journals: Discover world-class research

Abstract

Background

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an uncommon neurological disease affecting the central nervous system (CNS). Numerous neurological disorders, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), acute transverse myelitis (ATM), and MOGAD, have been reported following the COVID-19 infection during the current COVID-19 pandemic. On the other hand, it has been suggested that patients with MOGAD may be at greater risk for infection (particularly in the current pandemic).

Objective

In this systematic review, we gathered separately 1) MOGAD cases following COVID-19 infection as well as 2) clinical course of patients with MOGAD infected with COVID-19 based on case reports/series.

Methods

329 articles were collected from 4 databases. These articles were conducted from inception to March 1^st, 2022.

Results

Following the screening, exclusion criteria were followed and eventually, 22 studies were included. In 18 studies, a mean ± SD time interval of 18.6 ± 14.9 days was observed between infection with COVID-19 and the onset of MOGAD symptoms. Symptoms were partially or completely recovered in a mean of 67 days of follow-up.

Among 4 studies on MOGAD patients, the hospitalization rate was 25%, and 15% of patients were hospitalized in the intensive care unit (ICU).

Conclusion

Our systematic review demonstrated that following COVID-19 infection, there is a rare possibility of contracting MOGAD. Moreover, there is no clear consensus on the susceptibility of MOGAD patients to severe COVID-19. However, obtaining deterministic results requires studies with a larger sample size.

Keywords

COVID-19 SARS-CoV-2 myelin oligodendrocyte glycoprotein MOGAD

Introduction

Throughout history, the world has witnessed various endemics, epidemics, and pandemics.¹ In 2002, severe acute respiratory syndrome (SARS-CoV), a single-stranded RNA (ssRNA) virus belonging to the Coronaviridae family, emerged as an epidemic in Guangdong, China. The Middle East respiratory syndrome coronavirus (MERS-CoV) was first reported in Saudi Arabia and became endemic in the Middle East in the following decade. In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged from the Hunan seafood market in Wuhan, China, and in a short time, spread throughout the world, so that by late March 8^th, 2021, 450 million people were reported to have been infected with COVID-19.^2,3

The primary symptoms of COVID-19 infection have been reported to have respiratory and cardiac manifestations. Furthermore, headache, dizziness, acute demyelinating encephalomyelitis (ADEM), delirium, Guillain-Barre syndrome, acute transverse myelitis (ATM), hypogeusia, hyposmia, ischemic stroke, multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) have been identified as neurological manifestations of the virus.^4-7

However, 1 question that needs to be asked is: “How do the neurotropic features of the SARS-CoV-2 virus trigger autoimmunity?” Several studies revealed that SARS-CoV-2 is able to cross the blood-brain barrier (BBB) and cause inflammation in the central nervous system (CNS), demyelination, and damage to axons.^8-10 One of the autoimmune conditions triggered by COVID-19 infection was MOGAD.¹¹

The pathophysiology of autoimmune diseases could be ongoing for years, and infections, including COVID-19, may trigger these diseases.^12,13 Literally defined, MOGAD is one of the autoimmune diseases of the CNS in which IgG antibodies target the myelin sheath. Although the phenotype of these patients is similar to those with MS and NMOSD, the main target of the MOG-IgG is the myelin oligodendrocyte glycoprotein.¹⁴ It is possible to detect MOG-IgG synthesis within the CNS of patients with MOGAD from the onset of the disease, and this is linked to the severity of the disorder.¹⁵ In MOGAD, complement deposition occurs in white matter, and reactive gliosis in the white and grey matter is associated with partial axonal preservation. Additionally, MOGAD differs from MS and NMOSD in terms of disability levels, CD4 infiltration, and MOG-IgG expression.¹⁶

Appraising available data demonstrated the possibility of high hospitalization rates in patients with neurologic disorders contracting COVID-19.^17-19 Furthermore, the possibility of hospitalization of MOGAD patients with COVID-19 has increased. That is why it is essential to review all cases in this regard.

Our study gives an account of a systematic review of the status of MOGAD cases following COVID-19 infection. Our second aim is to provide an overview of the status of COVID-19 in patients with MOGAD.

Methods

Literature Search

We searched PubMed (Medline), Scopus, Web of Science, and Embase databases from inception to March 1^st, 2022. Moreover, gray literature, including the references of the included articles and review studies, and conference abstracts, was searched. Our search strategy in databases included input such as: (“Myelin-Oligodendrocyte Glycoprotein” OR (Glycoprotein AND Myelin-Oligodendrocyte) OR “Myelin Oligodendrocyte Glycoprotein” OR “MOG Glycoprotein” OR “glycoprotein MOG” OR “MOG protein” OR “myelin oligodendroglial glycoprotein” OR “myelin-oligodendrocyte glycoprotein” OR “protein MOG”) AND (“COVID 19” OR “COVID-19 Virus Disease” OR “COVID 19 Virus Disease*” OR “COVID-19 Virus Disease*” OR (Disease AND “COVID-19 Virus”) OR (“Virus Disease” AND COVID-19) OR “COVID-19 Virus Infection*” OR “COVID 19 Virus Infection” OR (Infection AND “COVID-19 Virus”) OR (“Virus Infection” AND COVID-19) OR “2019-nCoV Infection” OR “2019 nCoV Infection*” OR (Infection AND 2019-nCoV) OR “Coronavirus Disease-19” OR “Coronavirus Disease 19” OR “2019 Novel Coronavirus Disease” OR “2019 Novel Coronavirus Infection” OR “2019-nCoV Disease” OR “2019 nCoV Disease” OR “2019-nCoV Diseases” OR (Disease AND 2019-nCoV) OR COVID19 OR “Coronavirus Disease 2019” OR (“Disease 2019” AND Coronavirus) OR “SARS Coronavirus 2 Infection” OR “SARS-CoV-2 Infection” OR (Infection AND SARS-CoV-2) OR “SARS CoV 2 Infection*” OR “COVID-19 Pandemic*” OR “COVID 19 Pandemic” OR (Pandemic AND COVID-19)). This syntax was customized and was searched based on each database.

Inclusion and Exclusion Criteria

All case reports and case series studies that had addressed MOGAD patients following COVID-19 infection were included. Besides, case reports and the case series on the presence of COVID-19 infection in MOGAD patients were encompassed in our review. Of note, all included articles were in English. Exclusion criteria consisted of review articles, irrelevant studies, animal studies, duplicated studies, other coronaviridae viruses, and study populations of MS and NMOSD-related studies.

Study Selection and Data Extraction

To select the studies, two researchers (HG and MSD) screened all the articles separately and in case of any disagreement, a third researcher (OM) resolved it. In the next step, two researchers (EMG and MSD) extracted the data from the articles. They reviewed their information in two separate tables (the first for MOGAD following COVID-19 and the second for MOGAD patients with COVID-19) reporting the following information: author, year and country, patients’ demographic data, disease duration, comorbidity, disease-modifying therapies (DMT), clinical and laboratory, findings associated with COVID-19 and MOGAD, the patients, hospitalization, treatments, follow-up, and outcomes.

Quality Assessment

To assess the quality of the articles, the Joanna Briggs Institute’s (JBI) critical appraisal tool for case reports/case series²⁰ was used separately by (OM) and (MSD), and any disagreement was resolved by a senior researcher (VS). Articles were evaluated according to the questions’ answers (Yes or No), and the ranking was done by evaluating “Yes” answers from 0 to 8 (0 to 10 for case series). Articles lower than the 4 ranking (5 ranking for case series) were considered low quality, and those higher than 4 ranking (5 ranking for case series) were presumed high-quality articles.

Results

Search Results

According to the PRISMA flow chart, all selected and eliminated articles are listed (Figure 1). Initially, 329 articles were obtained from various databases. Following elimination of duplicates, 234 articles remained. Afterward, by screening all of the articles, the full texts of 87 articles were collected, and finally, 22 articles were included. The data was extracted from the articles, and the results were laid out in Table 1 and Table 2. Table 1 provides information about patients who developed MOGAD following COVID-19, and Table 2 provides information on COVID-19 outcomes in MOGAD patients. In addition, quality assessment was carried out and is listed in the tables.

Figure 1.

PRISMA Flow Diagram: includes details our search and selection process applied during the systematic review.

Table 1.

Demographic and clinical characteristics according to MOGAD patients following COVID-19 infection. MOGAD = Myelin oligodendrocyte glycoprotein antibody disease, MRI = Magnetic resonance imaging, NR = Not reported, MRC = Medical research Council, PCR = Polymerase chain reaction, CSF = Cerebrospinal fluid, Pro = Protein, WBC = White Blood Cell, Glu = Glucose, PLEX = Plasma exchange, Rt = Right, Lt = left, Ig = immunoglobulin, ESR = erythrocyte sedimentation rate, FLAIR = Fluid-attenuated inversion recovery, MOCA = Montreal cognitive assessment, AG = Antigen, OP = Opening pressure, EEG = Electroencephalogram, IVIG = Intravenous Immune globulin,OCB = Oligoclonal band, CRP = C-reactive protein, LDH = lactate dehydrogenase, OCD = Optical coherence tomography, CXR = Chest x-ray, BCVA = Best corrected visual acuity, RAPD = Relative afferent pupillary defect, VFD = Visual field defect, VA = Visual Acuity, pRNFL = Peripapillary retinal nerve fiber layer, ON = Optic neuritis, ADEM = Acute disseminated encephalomyelitis, VDRL = Venereal disease research laboratory test, N.E = Neurological examination, NPDR = Non-proliferative diabetic retinopathy, NT-pro BNP = N-terminal pro B-type natriuretic peptide, CK = Creatine kinase, ALT = Alanine transaminase, AST = Aspartate transaminase, HbA1c = High glycated hemoglobin, VRS = Verbal rating scale, mGluR1 = Metabotropic glutamate receptor 1, CFF = Critical flicker frequency, GP = Goldman perimetry, β2-MG = β2-microglobulin, MBP = Myelin basic protein, d = Day(s), w = Week(s), m = Month(s).

Author/Year/Country	Age/Gender	Comorbidities	COVID-19 Presentation	COVID-19 Diagnosis	COVID-19 Outcome	Time Interval	MOGAD Presentation	MRI Findings	Other Findings	MOGAD Acute Treatment	MOGAD Follow-up	Quality Assessment
Pinto et al¹¹/2020/United Kingdom	44/Female	NR	-Respiratory symptoms -Pruritus	PCR +	Not Hospitalized	1 w	-Hand incoordination -Aphasia -Visual and sensory -Inattention -Weakness	Brain: T2-hyperintensity within the centrum semiovale bilaterally in a periventricular location, extending along the Lt temporal and occipital horns and into the subcortical deep white matter bilaterally, more extensive in the Lt hemisphere Perivascular enhancement within the lesions, multiple cystic spaces without CSF signal consistent with enlarged perivascular spaces	CSF: WBC↑ Pro↑ Glu↑ Serum: MOG-IgG+ MRC: 4/5	Steroids PLEX	18 d later: Normal speech Full power No visual or sensory inattention MRI 17 d later: Residual white matter vasogenic edema No evidence of residual perivascular contrast-enhanced	6 out of 8
Sawalha et al²¹/2020/United States	44/Male	None	-Dyspnea -Cough	PCR+ IgG+	Not Hospitalized	2 w	-Bilateral eye pain -Vision loss	Brain: Enhancement in Rt optic nerve	CSF: Glu↑ Serum: ESR↑ Vitamin B12 ↑ Eye Exam: Rt:20/200 RAPD Lt: Superior arcuate VFD VA:20/30	Steroids	By day of discharge: Complete restoration of vision in the Lt eye Remarkable but not complete vision recovery in the Rt eye	7 out of 8
Peters et al²²/2021/United States	23/Male	-Childhood non-febrile seizures	-Headache	Rapid AG test- PCR+	NR	5 w	-Dysesthesias -Anomic aphasia -Decreased verbal fluency -Inattention -Impaired delayed recall -Cognitive decline -Headache -Fever -Fatigue -Personality changes -Seizure	Brain: Diffuse Lt hemispheric cortical T2-FLAIR hyperintensity, most pronounced in the Lt occipital and posterior temporal lobes, Lt -hemispheric leptomeningeal enhancement	CSF: IgG↑ IgG index↑ OP↑ Serum: MOG-IgG+ EEG: Frequent Lt posterior temporal rhythmic delta activity and epileptiform spikes MOCA score:20/30	Steroids	8 w later: Subjective cognitive symptoms resolved Normal delayed recall MRI brain 2 w later: Improvement in the Lt-hemispheric FLAIR hyperintensity and resolution of the leptomeningeal enhancement	7 out of 8
Ahsan et al²³/2021/United States	7/Female	None	None	PCR - IgG+ Next week: PCR+	Not Hospitalized	1 w	-Epilepticus -Aphasia -Fever -Todd’s paralysis -Headache -Encephalopathy -Abdominal pain -Dysarthria -Altered mental status -Seizure	Brain: Restricted diffusion and cortical edema	CSF: WBC↑ Multiple OCB Serum: MOG-IgG+ EEG: Abnormal cerebral slowing with Lt focal slowing	IVIG	Upon follow-up: almost returned to her baseline with mild dysarthria	7 out of 8
Khan et al²⁴/2021/India	11/Male	NR	-Fever	PCR+ IgG+	Not Hospitalized	4 d	-Ophthalmodynia 4days after: -Bilateral vision loss Two weeks later: -Bilateral Conjunctival -Congestion -Painful eye movement -Unilateral loss of vision	Brain: Bilateral asymmetrical ON, involving intraorbital and intracanalicular portion on the Rt and intraorbital portion on the Lt Altered signal intensities: segmental, Diffuse: in the Rt intraorbital optic nerve and patchy in the Lt intraorbital optic nerve with the enhancement of the optic nerve sheath in the Rt orbit consistent	CSF: Lymphocytic pleocytosis Serum: MOG-IgG+ Eye Exam: Sluggishly reactive pupils Rt: Vision of <N/36 Disc edema of grade 3 RAPD Lt: Vision 6/9	Steroids	10 d later: Rt eye vision improved to 6/9 and Lt eye to 6/6	4 out of 8
Zhou et al²⁵/2020/United States	26/Male	NR	-Cough	PCR+	Not Hospitalized	Few d	-Eye movements pain -Vision loss -Lower limb numbness -Neck discomfort with forward flexion	Brain: Avid, uniform enhancement, thickening of both optic nerves extending from the globe to their intracranial prechiasmal segments without overt involvement of the chiasm Spine: Patchy T2 hyperintensities in the lower cervical and upper thoracic spinal cord, mild central thickening, gadolinium enhancement	CSF: WBC↑ OCB Serum: OCB MOG-IgG+ Eye exam: ON Bilateral disc edema Venous congestion Rt: Hand motion vision Rt RAPD Retinal perivenous hemorrhage Lt: Vison 20/250	Steroids	3 w later: 20/30 vision in both eyes Complete resolution of disc edema	8 out of 8
Kogure et al²⁶/2021/Japan	47/Male	-Rt adrenal resection -Recurrent paranasal sinusitis	None	PCR+	Not Hospitalized	2 d	-Lt eye pain -VFD	Brain: Bilateral uniform enhancement along with optic nerve sheaths(Lt-dominant)	Serum: ESR↑ MOG-IgG+ Eye exam: Lt:Decimal VA .2, RAPD Eye exam: Average critical flicker frequency value: 42 Hz in the Rt eye 20 Hz in the Lt eye	Steroids	2 w later: VA improved, Lt RAPD disappeared	7 out of 8
Zoric et al²⁷/2021/Serbia	63/Male	-Hypertension -Diabetes -Cluster headaches	-Fatigue -Dyspnea -Cough -Fever	PCR – IgM+ IgG+	Hospitalized-Discharged	4 w	-Blurred vision in Rt eye -Headache	Brain: Microangiopathic and cortical reductive signs Neuroglial cyst on the Rt temporal side Spine: Spondyloarthrosis and hyperostosis.	Serum: ESR↑ CRP↑ D-dimer↑ LDH↑ Ferritin↑ Glu↑ lymphopenia VDRL+ CXR: Bilateral bronchopneumonia Eye Exam: Small papillary edema on Rt fundus Partial swelling of the optic nerve RAPD VA:20/630	Steroids	3 m later: VA and computed visual field on the Rt eye:normal 20/20 The visual evoked potentials:slightly prolonged latency of the p100 wave, and OCT:slight thinning of optic nerve fibers and ganglion cells after ON	7 out of 8
Rojas-Correa et al²⁸/2021/Spain	69/Male	Diabetes	-Fever -Rhinorrhea -Cough	PCR – IgG +	Hospitalized-Discharged	45 d	-Vision loss -Pain with eye movements	Brain: Extensive and uniform contrast enhancement of both optic nerves and sheaths Spine: Normal	Serum: MOG-IgG+ vitamin D↓ CRP↑ D dimer↑ LDH↑ Ferritin↑ Eye Exam: Bilateral disc edema Rt: BCVA:20/60 RAPD Lt: BCVA:20/30 OCT: Increase in the thickness of the pRNFL Fluorescein angiography: Dye leakage in both optic disc CXR: Rt multi-lobar reticulo-nodular pattern	Steroids	24 w after onset: BCVA:20/30 on the Rt eye and 20/25 on the Lt eye Stable visual fields No progression of optic atrophy A further MRI: Normal MOG-IgG test assay: Negative	7 out of 8
Cay-Martinez et al²⁹/2021/United States	7/Female	None	None	PCR – IgG +	Not Hospitalized	1 w	-Facial palsy -Weakness -Axial and peripheral tone↓ -Hypoesthesia -Anuria	Brain and Spine: Extensive demyelinating lesion	CSF: Lactate↑ WBC↑ RBC↑ Pro↑ Serum: WBC ↑ MOG-IgG+ N.E: Loss of patellar and ankle reflexes Mute plantar reflexes	Steroids PLEX IVIG	5 m later: Resolved sensory deficits Improvement in leg strength Increased deep tendon reflexes Micturate on her own MOG-IgG-	7 out of 8
Lindan et al³⁰/2021/United States	4/Male	None	NR	PCR+	NR	NR	-Seizures -Limb dysfunctions	Brain: ADEM-like changes on coronal T2-weighted images and axial FLAIR	NR	NR	Markedly recovered	3 out of 8
Jumah et al³¹/2021/United stats	61/Male	None	-Fever -Chills	PCR-	NR	1 d	-Urine retention -Weakness -Decreased sensation	Brain: Unremarkable Spine: Non-enhancing T2 hyperintense lesions of variable length in the mid-thoracic spinal cord	CSF: HHV6 PCR+ Serum: CRP↑	PLEX Streoids	5 w later: Paraplegia improved Minimal residual sensory and bladder symptoms	7 out of 8
Jossy/2021/India³²	38/Male	NR	NR	PCR+	NR	6 w	-Lt vision loss -Unilateral pain in eye movement	Brain: orbital hyperintense lesions along both optic nerves suggestive of demyelination	Eye Exam: Rt: BCVA:20/20 Lt: Grade III RAPD	Steroids	2 m later: BCVA improved to 20/20 in Lt eye on day 7 with no further recurrence	4 out of 8
Da costa/2021/Portugal³³	31/Male	-Asthma -Obstructive Sleep apnea	-Odynophagia -Anosmia -Ageusia -Fever -Malaise	PCR+	Not Hospitalized	21 d	-Dysesthesia in the periumbilical, second and third fingers of both hand, and lower limb -Perineal hyperesthesia Urinary retention	Spine: longitudinally extensive (T2 to T10) T2-hyperintense lesion located to the central spinal cord with mild gadolinium enhancement	CSF: Pleocytosis Pro↑ OCB+ MOG-IgG+ SARS-CoV-2 IgG in CSF and serum N.E: Sensory abnormalities and pyramidal tract involvement Lower body hyperalgesia Tactile dysesthesia with T10 dermatome level Pathologic patellar Grade 3 achilles deep tendon reflexes Bilateral extensor plantar response Thoracic medullary syndrome with possible conus involvement	Steroids Pregabalin	6 m later: Almost complete resolution of the sensitive abnormalities Mild urinary retention symptoms	7 out of 8
Ide/2022/Japan³⁴	24/Female	NR	-Headache -Myalgia -High fever	PCR+	Not Hospitalized	3 w	-Vision loss in Lt eye -Numbness -Difficulty in urinating and defecating	Brain: Faint T2 extension lesions around the trigone and inferior horn of the Lt lateral ventricle, near the ventricular wall above the trigone of the Rt ventricle, and bilaterally in the subcortical frontal lobes. Small, scattered lesions in the cerebral white matter. Contrast enhanced linear areas were seen at the margins of the lesions in the Rt superior frontal gyrus Spine: Scattered mottled or linear T2 high-signal lesions at the C4-C5, C5-C6, T3-T4, T6-T7, and T11-12 levels Each lesion had a faint contrast effect	CSF: Pleocytosis Pro↑ β2-MG↑ IgG↑ MBP↑ OCB+ Eye exam: visual acuity: 0.6 Redness of the Lt optic nerve papilla CFF in Lt eye: 23 Hz GP: Decrease in sensitivity around the central area of Lt eye Brain CT: Lt ON Romberg test +	Steroids	4 m later: After discharge showed no new lesions, and the known lesions had regressed	7 out of 8
Durovic/2021/Germany³⁵	22/Male	None	-Fever -Neck stiffness -Weakness -Loss of smell -Loss of taste	PCR+	Not Hospitalized	few d	-Severe headache	Brain: Multiple disseminated pathological T2 and FLAIR hyperintensities, predominantly cortically, without any contrast enhancement	CSF: Pleocytosis MOG-IgG+ mGluR1-Ab+ N.E: Mild impairment in executive function Serum MOG-IgG+ VRS:8/10	Steroids	2 m (63 d) later: no residual symptoms, no restrictions, and no medication	7 out of 8
Ali/2021/Qatar³⁶	45/Male	-Diabetes -Hypotension -Dyslipidemia	-Fever -Headache -Cough -Dyspnea	PCR+	Not Hospitalized	1 m	-Bilateral painless loss of vision	Brain: A tiny right deep frontal acute ischemic stroke, distal intra-orbital optic nerve sheath faint enhancement	CSF: pro slightly ↑ Serum: Ferritin↑ CRP ↑ LDH↑ IL-6↑ Urea↑ NT-pro BNP↑ Creatinine↑ Troponin- T↑ CK↑ ALT↑ AST HbA1c↑ Eye Exam: Rt: Perception of light Severe NPDR Weiss ring floaters Peripheral flat retinal break Peripheral degeneration Lt: Severe NPDR Peripheral Degeneration CXR: Accentuated bronchovascular and perihilar marking with multifocal patchy ground-glass opacities in the bilateral lung field	Steroids	3 months later: Transferred to the rehabilitation center and neuro-ophthalmology clinic	7 out of 8
Sinha/2021/India³⁷	11/Female	None	-Fever -Cough	PCR+	Not Hospitalized	10 d	-Painless, progressive diminution of vision in both eyes (Rt > Lt)	Brain: Conus along with focal lesion in pons and in middle cerebellar peduncle Bilateral symmetrical optic nerve enhancement Spine: Multifocal patchy hyperintense lesions	Eye exam: Swinging flashlight: Grade 4 in Rt RAPD Lt: Direct reflex N.E: Brisk deep tendon jerks Extensor plantars Visual evoked: Rt: No response Lt: delayed P100 latency MOG-IgG+	IVIG	2 W later: Visual acuity in both the eyes improved to 4/60 with a near visual acuity of N36 RAPD Grade 2+ was still present in the Rt eye when compared with Lt eye	5 out of 8

Table 2.

Demographic and clinical characteristics according to MOGAD patients with COVID-19 infection, DMT = Disease Modifying Therapies, PCR = Polymerase chain reaction, NR = Not reported, IVIG = Intravenous Immune globulin.

Author/Year/Country	Age/Sex	Disease duration(year)	Comorbidity	DMT	Initial COVID-19 symptoms	COVID-19 Treatments	Covid Diagnose	Outcome	Quality Assessment
Woodhall³⁸/2020/UK	39/Female	11	None	Mycophenolate mofetil	Malaise Coryzal, Sweating Postural Dizziness	NR	PCR+	NR	7 out of 8
Masuccio³⁹/2020/Italy	31/Female	12	None	Rituximab Tocilizumab	Anosmia Myalgia	NR	PCR+	NR	8 out of 8
Louapre⁴⁰/2021/France	45/Female	15	None	Mycophenolate mofetil	Fever Cough Dyspnea	NR	PCR+	NR	7 out of 10
	40/Female	2	None	Rituximab	Anosmia Headache Digestive disorders	NR	Not tested	NR
	65/Male	4	None	Rituximab	Anosmia Asthenia Digestive disorders	NR	PCR+	NR
	37/Male	17	None	Mycophenolate mofetil	Fever Cough Dyspnea Anosmia Asthenia Headache	NR	IgG/IgM +	NR
	65/Male	3	None	Rituximab	Fever Cough Asthenia Anosmia	NR	PCR+	NR
Newsome⁴¹/2021/North America countries	67/Female	15	Cancer, Chronic lung disease, Diabetes	Mycophenolate mofetil	NR	Hydroxychloroquine, Steroids	NR	Hospitalized-ICU	8 out of 10
	54/Male	3	Hypertension	Rituximab	NR	Chloroquine, Azithromycin, Oxygen therapy	NR	Hospitalized- ICU
	19/Female	3	None	Mycophenolate mofetil	NR	Hydroxychloroquine, Azithromycin, other antibiotics	NR	Hospitalized-Discharge
	26/Female	2	Obesity	Rituximab	NR	None	NR	Not hospitalized
	58/Female	7	None	None	NR	Steroids	NR	Not hospitalized
	32/Female	3	Morbid obesity	Rituximab	NR	Azithromycin	NR	Not hospitalized
	43/Female	2	Diabetes, Hypertension, Obesity	Azathioprine	NR	Azithromycin	NR	Not hospitalized
	20/Female	8	Migraines	Fingolimod	NR	None	NR	Not hospitalized
	62/Female	2	None	Rituximab	NR	Acetaminophen	NR	Not hospitalized
	26/Female	2	None	Rituximab	NR	NR	NR	Not hospitalized
	64/Female	0	Diabetes, Hypertension, Hyperlipidemia, Obstructive sleep apnea	Rituximab	NR	None	NR	Not hospitalized
	25/Female	15	None	IVIG	NR	Bamlanivimab	NR	Not hospitalized
	69/Male	4	Cancer, Hypertension	None	NR	None	NR	Not hospitalized
	58/Male	2	Hypertension, Obesity	Rituximab	NR	Unknown monoclonal antibody infusion	NR	Hospitalized-ICU
	27/Female	4	None	Azathioprine	NR	None	NR	Not hospitalized
	27/Male	NR	None	NR	NR	NR	NR	Not hospitalized
	38/Female	15	None	Rituximab	NR	NR	NR	Hospitalized-Discharge
	17/Male	2	NA	None	NR	None	NR	Not hospitalized
	60/Male	3	None	None	NR	None	NR	Not hospitalized
	20/Female	11	None	None	NR	None	NR	Not hospitalized

New MOGAD Cases Following COVID-19 Infection

18 new cases of MOGAD following COVID-19 infection were included. The female-to-male ratio was 1:2.6 and the mean ± SD age of the participants was 32 ± 20.4 years. The most common comorbidities of the patients were hypertension and diabetes, and a positive PCR result was obtained in 77.7% of cases. Additionally, the most common symptoms associated with COVID-19 were fever and cough, and only 2 patients were hospitalized.

The mean ± SD time interval between the time of contracting COVID-19 and the onset of MOGAD symptoms was 18.6 ± 14.9 days. As for MOGAD, the majority of lesions were located in the optic nerve and the cerebral cortex. Lesions were also found in spinal MRIs, ranging in size from small to extensive. Most MOGAD cases presented visual problems at the onset. 61.1% of patients were positive for serum MOG-Ab, and their acute treatment of patients was as follows: 88% (15 out of 17) of them received steroids, 18% (3 out of 17) received intravenous immune globulin (IVIG), and 18% (3 out of 17) carried out plasma exchange (PLEX). A partial or complete recovery of symptoms was achieved after a mean of 67 days of follow-up.

COVID-19 Infection in MOGAD Patients

Overall, 27 patients were enrolled. The mean ± SD age of patients was 42 ± 17.1 years, with a female-to-male ratio of 2:1. The mean ± SD of COVID-19’s duration was 6.4 ± 5.3 days in patients with a history of MOGAD. Moreover, the most common comorbidity among them was hypertension, and about 44.4% were undergoing rituximab therapy. Based on available data, 5 out of 6 patients showed positive PCR for COVID-19, 25% were hospitalized, and 15% were admitted to ICU. The most common symptoms of COVID-19 in the MOGAD population were anosmia, fever, and cough.

Discussion

Post-viral Infection Neurological Complications

Since the beginning of the COVID-19 pandemic in late 2019, many studies worldwide encompassed the effects of this infection on all aspects of human health.^42,43 Regarding the reports of MOGAD following COVID-19 infection, it was essential to know how the virus can trigger autoimmunity and how it acts on patients with autoimmune disorders. Several studies indicated that other viruses can also trigger various neurological complications. According to Mailles et al. study, bornavirus, Lassa fever virus(LFV), Ebola, zika, chikungunya, and herpes simplex virus (HSV) cause encephalitis,⁴⁴ a dengue virus causes Guillain-Barré syndrome,⁴⁵ NMOSD and ATM^46,47 The SARS-CoV-2 virus is no exception to the norm and is expected to cause neurological complications.⁴⁸

The Effects of COVID-19 on the CNS

With regards to the infection’s transmission to the CNS, 2 hypotheses are possible. In the hematogenous route, the invasive agent crossed the BBB through the bloodstream. The COVID-19 infection invades the CNS following binding to angiotensin-converting enzyme (ACE2) receptors present in the outer membrane of lung cells and several other tissues, or is transported with other immune cells to enter the CNS. Afterward, it invades endothelial and epithelial cells, or leukocytes. In the retrograde route, the virus invades neurons with axonal transport machinery. Consequently, these 2 routes causes inflammation in the CNS.^10,49 Therefore, not only do glial cells secrete IL-6, IL-12, IL-15, and TNFα, but also the occurrence of a cytokine storm is possible.⁵⁰

By the same token, COVID-19 associated with acute respiratory distress syndrome (ARDS) exhibits pathological characteristics such as pulmonary edema and hyaline membrane formation. These factors may cause gas exchange disorders and hypoxia in the central nervous system. Anaerobic metabolites in the mitochondria and acid metabolites in the brain are excessively accumulated in hypoxia, resulting in the swelling of the cells of the brain and obstruction of blood flow to the brain.⁵¹

A number of data originating from virus and human antigen sets demonstrating molecular mimicry have been used to support the mimicry concept. In the presence of virus proteins, activated B cells proliferate, differentiate into plasma cells, which are then capable of producing antibodies. They are produced to combat the infection, but mistakenly attack similar proteins that share extensive amino acid homology with human antigens.⁵²

Moreover, infection with viruses is associated with an inflammatory response, activating myelin-specific T cells, and this can result in early or delayed degeneration of myelin. The literature has historically reported that the genetically similar SARS-CoV-1⁵³ and the MERS-CoV,⁵³ are associated with central demyelination. In several experimental studies, the murine coronavirus infection of susceptible mice was found to result in demyelinating lesions similar to MS, as well as the presence of the virus' RNA sequences and its antigen.⁵⁴ Furthermore, the CNS may be compromised through ischemia–hypoxia or latent immune-mediated mechanisms in response to severe respiratory infections. In addition to its neurotropic and neuroinvasive properties, SARS-CoV-2 can also cause neurological damage directly, by binding to ACE2 receptors that are ubiquitous, including the central nervous system, or by passing through the Virchow Robin spaces through blood circulation. It is also believed that delayed brain damage is caused by an undesired immune response following acute infection, which leads to demyelination of the brain.⁵⁴

According to similar studies, infection causes a CNS-inflammatory disease mediated by CD4⁺ T cells that targets MOG protein, which then induces the recruitment and activation of MOG-specific B cells in peripheral lymph nodes draining into the CNS, which in turn produces MOG antibodies. It is also possible for a direct CNS infection to cause a peripheral circulation of CNS antigens, which in turn results in an immune response against MOG in demyelinating diseases. By using molecular mimicry, encephalitogenic T cells could be activated in the periphery after infection, resulting in inflammation in the central nervous system and an immune response against MOG.⁵⁵

Moreover, COVID-19 may induce autoimmunity in various ways, including through molecular mimicry, viral persistence, epitope spreading, and neutrophil extracellular trap (NET) formation.⁵⁶ A NET is a structure that resembles a net and consists of DNA-histone complexes and pro-inflammatory proteins released by neutrophils when they become activated.⁵⁷ As a result of these events, demyelination and degeneration of neurons occur, and neurodegenerative diseases, including MS, NMOSD, ATM, etc. are caused.⁴⁷

MOGAD Mechanism and Patients’ Characteristics

MOGAD is a rare neuro-inflammatory disorder,⁵⁸ and there are several hypotheses that explain why MOGAD is triggered by COVID-19 infection (Figure 2). This virus is able to stimulate the demyelination of neurons and lead to MOG-Ab production by plasma cells.^59,60 Also, endothelial cells in multiple organs, including the brain, express ACE2, which are the main targets of SARS-COV-2. Symptoms of MOG-related demyelination may be caused by lymphocytic endothelitis associated with COVID-19 infection, which may facilitate the entry of MOG-IgG into the brain.³⁷

Figure 2.

Possible mechanism of COVID-19 in the CNS and causing MOGAD. Created with: Biorender.com.

Another hypothesis is that the demyelination of neurons produces antigens that can cross the BBB and enter the bloodstream. This is why MOG antigens are detected mainly by immune cells and lead to the production of MOG-Abs.⁶¹ The stimulation of B and T cells by viral infection is the final hypothesis proposed by Reindl et al. wherein the subsequent encounter of the virus leads to the development of IgG associated with MOG-Ab, and the virus then binds to cells in the CNS.⁵⁵ Following this binding, antibody-dependent cell-mediated cytotoxicity (ADCC) occurs,⁶² Finally, macrophages and T-cells enter the CNS,⁶³ activate the complement cascade,⁶⁴ and cytokine storm is developed.⁶⁵ Furthermore, the MOG-Ab causes white and gray matter to be affected,⁶⁶ while also triggering gliosis,⁶⁷ demyelinating lesions around small to medium-sized venules,⁶⁸ as well as acute plaques in the cortical, intracortical, and subpial areas.^68-71 Narayan et al. reported that this disorder causes lesions in the optic nerve,⁷² brain,⁷³ and spinal cord.⁷⁴ Characteristics of MOGAD patients include optic neuritis,⁷⁵ ADEM,⁷⁶ myelopathy,⁷⁷ and brainstem syndrome⁷⁷ associated with MOG-Ab⁷⁸ and preserving aquaporin 4 (AQP4)-IgG.⁷¹

MOGAD Diagnosis Following COVID-19 Infection

Studies by Netravathi et al. described the symptoms of MOGAD patients as seizures, encephalitis, leukodystrophy, meningitis, cranial neuropathy, myeloradiculopathy,⁷⁷ and fever.⁷⁹ In our review, most symptoms of MOGAD patients were ON, vision loss, weakness, headache, and seizure following a period of COVID-19 infection. Moreover, the symptoms of MOGAD appeared after a mean ± SD of 16.6 ± 14.9 days after the onset of COVID-19, while in other demyelinating diseases, onset symptoms occurred following about 10 days.^80-84 According to a systematic review of CNS demyelination published by Ismail et al. in 2021,⁵⁴ 3 cases of MOGAD have been reported. Although our research supports the findings of the previous systematic review, we report more cases than the previous studies.

Routine treatments for acute MOG antibody disease are intravenous methylprednisolone,⁸⁵ PLEX,⁸⁶ and IVIG.⁸⁷ Administration of Steroids for the chronic phase and IVIG for the acute phase were common treatments for patients with MOGAD. Adequate follow-ups were performed after discharge, and all of them regained relative improvement.

Interestingly, according to a Canadian study by Kaseka et al., the number of admissions due to MOGAD decreased in COVID-19 lockdowns.⁸⁸ The study concluded that by controlling viral infections, the incidence of MOGAD can be reduced to some extent.

MOGAD Patients With COVID-19 Infection

A number of studies have found that the risk and susceptibility of COVID-19 infection among populations with neurological disorders were different.^89-91 There was a 25% hospitalization rate and 15% ICU admission rate for MOGAD patients with COVID-19, respectively, whereas 14% of MOGAD patients were hospitalized after COVID-19. In this study, no COVID-19 mortality for MOGAD patients was reported, whereas the mortality rate of COVID-19 in the normal population was 1.5-3.5%.⁹² Reindl et al. also explained that MOG antibodies exacerbated CNS inflammation caused by a viral infection that allowed the infiltration more immune cells into the brain and spinal cord by MOG-IgG.⁵⁵

13 MOGAD patients with COVID-19 were reported in an original study by Sen et al. study, in which 2 patients were reported with symptoms of severe COVID-19 infection and one patient was hospitalized. The number of relapses is nearly equal before and after COVID-19.⁹³ These results are consistent with those reported in other case reports and case series which indicate that COVID-19 is mild in these patients and few hospitalizations are associated with it.

Limitations

In this systematic review, at first, we comprehensively assessed all case reports on new cases of MOGAD following COVID-19 infection. Secondly, COVID-19 infection outcomes in MOGAD patients were collected. Although our knowledge of MOGAD patients' pre-and post-COVID-19 conditions is primarily limited, this is the first systematic review that has been carried out in this regard. Furthermore, the limited number of case reports and case series, and the heterogeneity of the collected data contributed to the incapability of conducting a meta-analysis.

Conclusion

In conclusion, there is no clear consensus that there is an association between COVID-19 and MOGAD. Moreover, a larger sample size is required to clarify this issue. The prospect of obtaining more studies with larger sample sizes about the status of MOGAD patients following COVID-19 and also the status of MOGAD patients during the development of COVID-19 infection serves as a continuous incentive for future research.

Footnotes

Author Contributions

All the authors listed in the manuscript have participated actively in preparing the final version of this case report.

Declaration of Conflicting Interests:

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding:

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Omid Mirmosayyeb

Mohammad Sadegh Dehghan

Vahid Shaygannejad

References

Huremović

. Brief history of pandemics (pandemics throughout history). In: Psychiatry of pandemics. Berlin, Germany: Springer; 2019:7-35.

Shereen

Khan

Kazmi

Bashir

Siddique

. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-98.

Ritchie

Mathieu

Rodés-Guirao

, et al. Coronavirus Pandemic (COVID-19). Our World in Data; 2020.

El-Anwar

Elzayat

Fouad

. ENT manifestation in COVID-19 patients. Auris Nasus Larynx. 2020;47(4):559-564.

Ahmad

Rathore

. Neurological manifestations and complications of COVID-19: a literature review. J Clin Neurosci. 2020;77:8-12.

Yavari

Raji

Moradi

Saeidi

. Demyelinating Changes Alike to Multiple Sclerosis: A Case Report of Rare Manifestations of COVID-19. Case Rep Neurol Med. 2020;2020:6682251.

de Ruijter

Kramer

Gons

RAR

Hengstman

GJD

. Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: A case report. Mult Scler Relat Disord. 2020;46:102474.

Tancheva

Petralia

Miteva

, et al. Emerging neurological and psychobiological aspects of COVID-19 infection. Brain Sci. 2020;10(11):852.

Zoghi

Ramezani

Roozbeh

Darazam

Sahraian

. A case of possible atypical demyelinating event of the central nervous system following COVID-19. Mult Scler Relat Disord. 2020;44:102324.

10.

Desforges

Le Coupanec

Dubeau

, et al.

Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?

Viruses. 2019;12(1):14.

11.

Pinto

Carroll

Nar

Varatharaj

Galea

. CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e813.

12.

Vogt

Hunt

Adluru

, et al. Cortical microstructural alterations in mild cognitive impairment and Alzheimer’s disease dementia. Cereb cortex. 2020;30(5):2948-2960.

13.

Sadeghmousavi

Rezaei

. COVID-19 and Multiple Sclerosis: Predisposition and Precautions in Treatment. SN Compr Clin Med [Internet]. 2020;2(10):1802-1807. https://www.embase.com/search/results?subaction=viewrecord&id=L2006055446&from=export

14.

Asseyer

Cooper

Paul

. Pain in NMOSD and MOGAD: a systematic literature review of pathophysiology, symptoms, and current treatment strategies. Front Neurol. 2020;11:778.

15.

Kwon

Kim

J-S

, et al. Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability. Neurol Neuroimmunol Neuroinflamm. 2022;9(1):e1095.

16.

Sharma

Bhatti

Danesh-Meyer

. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review. Clin Exp Ophthalmol. 2021;49(2):186-202.

17.

BArzegar

Mirmosayyeb

Gajarzadeh

, et al. COVID-19 among patients with multiple sclerosis a systematic review. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1001.

18.

Frontera

Sabadia

Lalchan

, et al. A prospective study of neurologic disorders in hospitalized patients with COVID-19 in New York City. Neurology. 2021;96(4):e575-e586.

19.

Amanat

Rezaei

Roozbeh

, et al. Neurological manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: a multicenter prospective clinical study. BMC Neurol. 2021;21(1):116-212.

20.

Moola

Munn

Tufanaru

, et al. Joanna Briggs Institute Reviewer’s Manual. The Joanna Briggs Institute; 2017. Chapter 7: Systematic reviews of etiology and risk.

21.

Sawalha

Adeodokun

Kamoga

G-R

. COVID-19-Induced Acute Bilateral Optic Neuritis. J Investig Med High Impact Case Rep. 2020;8:2324709620976018. https://www.embase.com/search/results?subaction=viewrecord&id=L2007412667&from=export

22.

Peters

Alhasan

Vogels

CBF

Grubaugh

Farhadian

Longbrake

. MOG-associated encephalitis following SARS-COV-2 infection. Mult Scler Relat Disord. 2021;50:102857.

23.

Ahsan

Jafarpour

Santoro

. Myelin oligodendrocyte glycoprotein antibody encephalitis following severe acute respiratory syndrome coronavirus 2 in a pediatric patient. Clin Exp Pediatr. 2021;64(6):310-312.

24.

Khan

Panwala

Ramadoss

Khubchandani

. Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease in a 11 Year Old with COVID-19 Infection. Indian J Pediatr. 2021;88(5):488-489.

25.

Zhou

Jones-Lopez

Soneji

Azevedo

Patel

. Myelin oligodendrocyte glycoprotein antibody–associated optic neuritis and myelitis in COVID-19. J Neuroophthalmol. 2020;40:398-402.

26.

Kogure

Kikushima

Fukuda

, et al. Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in a COVID-19 patient: A case report. Medicine (Baltimore). 2021;100(19):e25865.

27.

Žorić

Rajović-Mrkić

Čolak

Mirić

Kisić

. Optic Neuritis in a Patient with Seropositive Myelin Oligodendrocyte Glycoprotein Antibody During the Post-COVID-19 Period. Int Med Case Rep J. 2021;14:349-355.

28.

Rojas-Correa

Reche-Sainz

Insausti-García

Calleja-García

Ferro-Osuna

. Post COVID-19 myelin oligodendrocyte glycoprotein antibody-associated optic neuritis. Neuro-Ophthalmology. 2021;46:115-121.

29.

Cay-Martínez

Shen

Silver

Vargas

. Postinfectious encephalomyelitis associated with myelin oligodendrocyte glycoprotein antibody in a pediatric patient with COVID-19. Pediatr Neurol. 2021;124:40-41.

30.

Lindan

Mankad

Ram

ASPNR PECOBIG Collaborator Group , et al. Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study. Lancet Child Adolesc Health. 2021;5(3):167-177.

31.

Jumah

Rahman

Figgie

, et al. COVID-19, HHV6 and MOG antibody: A perfect storm. J Neuroimmunol. 2021;353:577521.

32.

Jossy

Jacob

Sarkar

Gokhale

Kaliaperumal

Deb

. COVID-19-associated optic neuritis - A case series and review of literature. Indian J Ophthalmol. 2022;70(1):310-316. https://www.embase.com/search/results?subaction=viewrecord&id=L636936280&from=export

33.

da Costa

Rato

Cruz

Valadas

Antunes

Albuquerque

. Longitudinally extensive transverse myelitis with anti-myelin oligodendrocyte glycoprotein antibodies following SARS-CoV-2 infection. J Neuroimmunol. 2021;361:577739.

34.

Ide

Kawanami

Eriguchi

Hara

. SARS-CoV-2-related Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease: A Case Report and Literature Review. Intern Med [Internet]. 2022;61(8):1253-1258. https://www.embase.com/search/results?subaction=viewrecord&id=L637206117&from=export

35.

Durovic

Bien

Isenmann

. MOG antibody-associated encephalitis secondary to Covid-19: case report. BMC Neurol. 2021;21(1):414.

36.

Ali

Jahangiri

Ali

, et al. Emerging Super-specialty of Neurology: Intraoperative Neurophysiological Monitoring (IONM) and experience in various neurosurgeries at a tertiary care hospital in Doha, Qatar. CUREUS. 2021;13(9):e20432.

37.

Sinha

Wander

Kapoor

Yadav

Kumar

Gulati

. Acute Demyelinating Syndrome (MOG Antibody Positive) Associated With COVID-19 Infection: A Widening spectrum. Clin Pediatr (Phila) [Internet]. 2021;60(13):501-503. https://www.embase.com/search/results?subaction=viewrecord&id=L2013410715&from=export

38.

Woodhall

Mitchell

Gibbons

Healy

Waters

Huda

. Case report: myelin oligodendrocyte glycoprotein antibody-associated relapse with COVID-19. Front Neurol. 2020;11:598531.

39.

Masuccio

Lo Re

Bertolotto

Capobianco

Solaro

. Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment. Mult Scler Relat Disord. 2020;46:102592.

40.

Louapre

Maillart

Papeix

, et al. Outcomes of Coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders. Mult Scler J [Internet. 2020;26(3 suppl):86-87. https://www.embase.com/search/results?subaction=viewrecord&id=L634020814&from=export

41.

Newsome

Cross

Fox

, et al. COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1065. https://www.embase.com/search/results?subaction=viewrecord&id=L636338772&from=export

42.

Cullen

Gulati

Kelly

. Mental health in the COVID-19 pandemic. QJM An Int J Med. 2020;113(5):311-312.

43.

Trindade

Ferreira

. COVID-19 pandemic’s effects on disease and psychological outcomes of people with inflammatory bowel disease in Portugal: A preliminary research. Inflamm Bowel Dis. 2021;27(8):1224-1229.

44.

Mailles

Stahl

J-P

Bloch

. Update and new insights in encephalitis. Clin Microbiol Infect. 2017;23(9):607-613.

45.

Kumar

Prabhakar

. Guillain-Barre syndrome occurring in the course of dengue fever. Neurol India. 2005;53:250-251.

46.

Carod-Artal

Wichmann

Farrar

Gascón

. Neurological complications of dengue virus infection. Lancet Neurol. 2013;12(9):906-919.

47.

Mirmosayyeb

Ghaffary

Bagherieh

Barzegar

Dehghan

Shaygannejad

. Post COVID-19 Infection Neuromyelitis Optica Spectrum Disorder (NMOSD): A Case Report-Based Systematic Review. Mult Scler Relat Disord. 2022;60:103697.

48.

Sepehrinezhad

Shahbazi

Negah

. COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective review. J Neurovirol. 2020;26:324-329.

49.

Koyuncu

Hogue

Enquist

. Virus infections in the nervous system. Cell Host Microbe. 2013;13(4):379-393.

50.

Bodro

Compta

Sánchez-Valle

. Presentations and mechanisms of CNS disorders related to COVID-19. Neurol Neuroimmunol Neuroinflamm. 2021;8(1):e923.

51.

Sun

Feng

. Complications and Pathophysiology of COVID-19 in the Nervous System. Front Neurol [Internet]. 2020;11:573421. https://www.embase.com/search/results?subaction=viewrecord&id=L633690451&from=export

52.

Damoiseaux

Dotan

Fritzler

, et al. Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmun Rev. 2022;21(3):103012.

53.

Gong

Zhang

, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415-424.

54.

Ismail

Salama

. Association of CNS demyelination and COVID-19 infection: an updated systematic review. J Neurol. 2022;269(2):541-576. https://www.embase.com/search/results?subaction=viewrecord&id=L2013440889&from=export

55.

Reindl

Di Pauli

Rostásy

Berger

. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013;9(8):455-461.

56.

Awada

Kang

, et al. Antineutrophil Cytoplasmic Autoantibody (ANCA)-Associated Vasculitis With Mucosal Involvement Following COVID-19 Pneumonia. Cureus. 2022;14(11):e31441.

57.

Torres-Ruiz

Absalón-Aguilar

Nuñez-Aguirre

, et al. Neutrophil extracellular traps contribute to COVID-19 hyperinflammation and humoral autoimmunity. Cells. 2021;10(10):2545.

58.

Ennis

Hunt

Rice

Bannan

Bradley

O’Callaghan

. Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Related Disease. Int J Mol Sci. 2020;22:100.

59.

Selter

Brilot

Grummel

, et al. Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology. 2010;74(21):1711-1715.

60.

Angileri

Legare

Marino Gammazza

Conway de Macario

Jl Macario

Cappello

. Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmun Rev. 2020;19(8):102591.

61.

Ramanathan

Dale

Brilot

. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016;15(4):307-324.

62.

Brilot

Dale

Selter

, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol. 2009;66(6):833-842.

63.

Luo

Chang

She

Kermode

Qiu

. Myelin oligodendrocyte glycoprotein antibody-associated disorders coexisting with ankylosing spondylitis: Potential association between demyelination and tumor necrosis factor inhibitors. Mult Scler Relat Disord. 2021;51:102889.

64.

Ambrosius

Michalak

Kozubski

Kalinowska

. Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management. Int J Mol Sci. 2020;22(1):100.

65.

Liu

Mori

Sugimoto

, et al. Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS. J Neurol Neurosurg Psychiatry. 2020;91(2):132-139.

66.

Shahriari

Yousem

Sotirchos

Newsome

. MOG Antibody Associated Disease: How it Differs From and Resembles Other Neuroinflammatory Disorders. AJR Am J Roentgenol. 2020;216:1031-1039.

67.

Carnero Contentti

Correale

. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation. 2021;18(1):208-218.

68.

Beltrán

Paunovic

Gebert

, et al. Archeological neuroimmunology: resurrection of a pathogenic immune response from a historical case sheds light on human autoimmune encephalomyelitis and multiple sclerosis. Acta Neuropathol. 2021;141(1):67-83.

69.

Zuroff

Benjamins

Bar-Or

Lisak

. Inflammatory mechanisms underlying cortical injury in progressive multiple sclerosis. Neuroimmunol Neuroinflammation. 2021;8:111-133.

70.

Lopez

Denkova

Ramanathan

Dale

Brilot

. Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. Clin Transl Immunology. 2021;10(7):e1316.

71.

Höftberger

Guo

Flanagan

, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020;139:875-892.

72.

Narayan

Simpson

Fritsche

, et al. MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;25:66-72.

73.

Juryńczyk

Tackley

Kong

, et al. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry. 2017;88(2):132-136.

74.

Mariano

Messina

Roca-Fernandez

Leite

Kong

Palace

. Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis. Brain. 2021;144(1):198-212.

75.

Chen

Bhatti

. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol. 2020;33(1):47-54.

76.

Simone

Monti

Amidei

, et al. Acute disseminated encephalomyelitis associated with anti-myelin oligodendrocyte glycoprotein (MOG-IGG) antibody in a patient with recent vaccination against SARS-CoV-2. J Neurol Sci. 2021;429:118167.

77.

Netravathi

Holla

Nalini

, et al. Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder. J Neurol. 2021;268(4):1419-1433.

78.

Mader

Kümpfel

Meinl

. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG-and MOG-IgG-associated diseases. Curr Opin Neurol. 2020;33(3):362-371.

79.

Lampros

De Broucker

Bonnan

. Fever is a common onset feature of MOG-IgG associated disorders (MOGAD). Mult Scler Relat Disord. 2021;49:102748.

80.

Valencia-Sanchez

Wingerchuk

. A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19. Mult Scler Relat Disord. 2020;42:102182.

81.

Havla

Schultz

Zimmermann

Hohlfeld

Danek

Kümpfel

. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. J Neurol. 2022;269(1):55-58. https://www.embase.com/search/results?subaction=viewrecord&id=L2012386834&from=export

82.

Motahharynia

Naghavi

Shaygannejad

Adibi

. Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccination: A need for reconsideration? Mult Scler Relat Disord. 2022;66:104035.

83.

Oguz-Akarsu

Ozpar

Mirzayev

, et al. Guillain-Barré syndrome in a patient with minimal symptoms of COVID-19 infection. Muscle Nerve. 2020;62(3):E54-E57.

84.

Notghi

AAA

Atley

Silva

. Lessons of the month 1: Longitudinal extensive transverse myelitis following AstraZeneca COVID-19 vaccination. Clin Med (Northfield). 2021;21(5):E535-e538. https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115982402&doi=10.7861%2Fclinmed.2021-0470&partnerID=40&md5=9360f33ede28727a7ec2ce34a8b7dc8f

85.

Kunchok

Krecke

Flanagan

, et al.

Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG–associated disorders (MOGAD)?

Neurology. 2020;94(2):85-88.

86.

Gospe

Chen

Bhatti

. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. Eye. 2021;35(3):753-768.

87.

Bruijstens

Neuteboom

Wendel

, et al. E.U. paediatric MOG consortium consensus: Part 4 - Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:32-40.

88.

Kaseka

Yea

Longoni

Yeh

. Impact of COVID-19 public health measures on myelin oligodendrocyte glycoprotein IgG-associated disorders in children. Mult Scler Relat Disord [Internet]. 2021;56:103286. https://www.embase.com/search/results?subaction=viewrecord&id=L2014936113&from=export

89.

Barzegar

Mirmosayyeb

Ebrahimi

, et al. COVID-19 Susceptibility and Outcomes among Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD): A Systematic Review and Meta-Analysis. Mult Scler Relat Disord. 2021;57:103359.

90.

Louapre

Collongues

Stankoff

, et al. Clinical Characteristics and Outcomes in Patients with Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020;77(9):1079-1088.

91.

Alonso

Silva

Garcea

, et al. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM. Mult Scler Relat Disord. 2021;51:102886.

92.

Baud

Nielsen-Saines

Musso

Pomar

Favre

. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020;20(7):773.

93.

Sen

Tuncer

Ozakbas

, et al.

The Turkish experience of Covid-19 Infection in people with NMOSD and MOGAD: a milder course?

Mult Scler Relat Disord. 2021;58:103399.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review

Abstract

Background

Objective

Methods

Results

Conclusion

Keywords

Introduction

Methods

Literature Search

Inclusion and Exclusion Criteria

Study Selection and Data Extraction

Quality Assessment

Results

Search Results

New MOGAD Cases Following COVID-19 Infection

COVID-19 Infection in MOGAD Patients

Discussion

Post-viral Infection Neurological Complications

The Effects of COVID-19 on the CNS

MOGAD Mechanism and Patients’ Characteristics

MOGAD Diagnosis Following COVID-19 Infection

MOGAD Patients With COVID-19 Infection

Limitations

Conclusion

Footnotes

Author Contributions

Declaration of Conflicting Interests:

Funding:

ORCID iDs

References